Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/26/28	$0.5367	+3.43%	1,52,868
27/26/27	$0.5189	+2.67%	13,24,168
26/26/26	$0.5054	-0.90%	3,96,739
23/26/23	$0.5100	+2.91%	3,23,719
22/26/22	$0.4956	-1.73%	72,342

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.5189USD

Average target price

20.00USD

Spread / Average Target

+3,754.31%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Jasper Therapeutics, Inc.

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Jasper Therapeutics, Inc.

Company calendar

Real-time Estimate Cboe BZX 09:25:28 28/10/2026 pm IST			5-day change	1st Jan Change
0.5360 ^USD	+3.30%		+6.42%	-70.67%

15/10	Jasper Therapeutics, Inc. Completes Enrollment of Iga Nephropathy Cohort of Phase 2 Basket Study Evaluating Vensobafusp Alfa	CI
29/09	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI

Market Cap	1.73Cr 1.55Cr 1.43Cr 1.3Cr 2.43Cr 164Cr 2.45Cr 17Cr 6.81Cr 86Cr 6.48Cr 6.34Cr 272.6Cr	P/E 2026 *	-	P/E 2027 *	-5.19x
Enterprise Value	1.73Cr 1.55Cr 1.43Cr 1.3Cr 2.43Cr 164Cr 2.45Cr 17Cr 6.81Cr 86Cr 6.48Cr 6.34Cr 272.6Cr	EV / Sales 2026 *	2.88x	EV / Sales 2027 *	-
Free-Float	97.45%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	JSPR	Delayed
CBOE	JSPR	Real-time

15/10	Jasper Therapeutics, Inc. Completes Enrollment of Iga Nephropathy Cohort of Phase 2 Basket Study Evaluating Vensobafusp Alfa	CI
29/09	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI
29/09	Jasper Therapeutics, Inc. Announces Management Changes, Effective October 9, 2026	CI
18/09	Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to NASDAQ Composite Index	CI
15/09	Jasper Therapeutics, Inc. Appoints Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President	CI
14/08	Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
12/08	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
05/08	Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors	CI
17/07	Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026	CI
17/07	Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall	MT
16/07	Kira Pharmaceuticals acquired Jasper Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.	CI
16/07	Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding	CI
02/06	Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value	CI

Jasper Therapeutics, Inc. Share Price

Stocks

JSPR

US4718712023

Biotechnology & Medical Research

Valuation: Jasper Therapeutics, Inc.

Chart: Jasper Therapeutics, Inc.

Latest news: Jasper Therapeutics, Inc.

Last Transcript: Jasper Therapeutics, Inc.

Analysts' recommendations: Jasper Therapeutics, Inc.

Press Releases: Jasper Therapeutics, Inc.

News in other languages: Jasper Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Jasper Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

12/08	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
15/05	RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk	MT
15/05	TD Cowen Downgrades Jasper Therapeutics to Hold From Buy	MT
23/03	UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25	MT
11/11	RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk	MT

07/10	Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants	AQ
16/09	Jasper Therapeutics Announces Key Regulatory and Clinical Appointments	AQ
09/09	Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
17/08	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
14/08	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ

19/25/19	USA-Les valeurs à suivre à Wall Street (actualisé)
16/21/16	MÄRKTE USA/Kaum verändert - Zwischen China-Hoffnung und Zinssorgen
15/21/15	MÄRKTE USA/Wall Street dreht leicht ins Minus
15/21/15	MÄRKTE USA/Wall Street mit Vorschusslorbeeren für Biden-Xi-Gipfel
15/21/15	MÄRKTE USA/Wall Street vor Biden-Xi-Gipfel leicht optimistisch

1 day	+3.30%
1 week	+6.42%
Current month	-7.47%
1 month	-14.27%
3 months	-15.21%
6 months	-42.27%
Current year	-70.67%

1 week	0.46	0.55
1 month	0.46	0.68
Current year	0.32	2.07
1 year	0.32	2.52
3 years	0.32	31.01
5 years	0.32	106.9
10 years	0.32	188.8

Manager	Title	Age	Since
Jeet Mahal CEO	Chief Executive Officer	54	06/01/2026
Matthew Ros COO	Chief Operating Officer	59	16/07/2026
Daniel Adelman CTO	Chief Tech/Sci/R&D Officer	68	23/03/2023

Director	Title	Age	Since
Jeet Mahal BRD	Director/Board Member	54	06/01/2026
Judith Shizuru BRD	Director/Board Member	70	04/09/2021
Kurt von Emster BRD	Director/Board Member	59	24/09/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/07/26	Judith Shizuru	Free	Founder	7,500	0.0267%
31/07/26	Patrick Crutcher	Free	Director	7,500	0.0267%
31/07/26	Thomas Wiggans	Free	Chairman	7,500	0.0267%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JASPER THERAPEUTICS, INC.	+3.30%	+6.42%	-77.06%	-92.46%	1.73Cr
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	6.35TCr
ARGENX SE	+2.25%	+1.78%	+12.38%	+83.04%	5.45TCr
LONZA GROUP AG	-1.10%	+0.90%	+10.35%	+101.99%	5.36TCr
IQVIA HOLDINGS INC.	+2.54%	+0.82%	+27.86%	+57.43%	4.48TCr
BEONE MEDICINES AG	+2.20%	-3.06%	+18.24%	+100.76%	4.16TCr
REVOLUTION MEDICINES, INC.	+0.74%	-3.03%	+223.87%	+926.68%	3.99TCr
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	3.25TCr
GENMAB A/S	+29.06%	+45.34%	+103.91%	+91.26%	2.67TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	2.34TCr
Average	+4.39%	+0.00%	+38.90%	+137.18%	3.8TCr
Weighted average by Cap.	+3.21%	-0.29%	+47.36%	+161.47%

	2026 *	2027 *
Net sales	60L 53.85L 49.72L 45.09L 84.27L 57Cr 85.31L 5.96Cr 2.37Cr 30Cr 2.25Cr 2.2Cr 95Cr	-
Net income	-	-63.86 -57.31 -52.92 -47.99 -89.69 -6.07T -90.79 -634.46 -251.97 -3.18T -239.7 -234.57 -10.08T
Net Debt	-	-